Hudson Bay Capital Management’s GSK GSK Stock Holding History

Hudson Bay Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-101,429	Closed	-$4.38M	–	1328
2025 Q3	$4.38M	Buy	+101,429	New	+$3.96M	0.01%	587
2025 Q1	–	Sell	-75,000	Closed	-$2.54M	–	1375
2024 Q4	$2.54M	Buy	75,000 +65,000	+650%	+$2.34M	0.01%	612
2024 Q3	$409K	Sell	10,000 -75,000	-88%	-$3.07M	﹤0.01%	731
2024 Q2	$3.27M	Buy	+85,000	New	+$3.58M	0.02%	456
2024 Q1	–	Sell	-326,884	Closed	-$12.1M	–	789
2023 Q4	$12.1M	Sell	326,884 -380,000	-54%	-$13.6M	0.08%	158
2023 Q3	$25.6M	Buy	+706,884	New	+$25.1M	0.2%	78
2022 Q4	–	Sell	-75,000	Closed	-$2.21M	–	1039
2022 Q3	$2.21M	Sell	75,000 -725,000	-91%	-$27.5M	0.02%	706
2022 Q2	$43.5M	Buy	+800,000	New	+$44.2M	0.33%	61
2018 Q1	–	Sell	-40,000	Closed	-$1.77M	–	795
2017 Q4	$1.77M	Sell	40,000 -8,000	-17%	-$370K	0.04%	341
2017 Q3	$2.44M	Buy	+48,000	New	+$2.44M	0.06%	226

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hudson Bay Capital Management's GSK Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of GSK (GSK) in Q4 2025, closing a stake of 101,429 shares — an estimated $4.38M sold.

Hudson Bay Capital Management first reported a position in GSK in Q3 2017 and held it in 10 quarters. The position peaked at $43.5M in Q2 2022. 998 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Hudson Bay Capital Management reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 101,429 GSK shares in Q4 2025, an estimated $4.38M.
Hudson Bay Capital Management first reported a position in GSK in Q3 2017 and held it in 10 quarters.
Hudson Bay Capital Management's GSK position peaked at $43.5M in Q2 2022.
998 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.